Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FTD

Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FTD

Background and Rationale

This comprehensive validation study addresses one of the most significant questions in neurodegeneration: how a single genetic mutation in C9orf72 can manifest as distinct diseases (ALS, FTD, or combined phenotypes). The C9orf72 hexanucleotide repeat expansion represents the most common genetic cause of both familial ALS (~40%) and familial FTD (~25%), yet the mechanisms underlying phenotypic diversity remain largely unknown. This research gap represents a critical barrier to developing targeted therapeutics and understanding fundamental disease processes.

...

Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FTD

Background and Rationale

This comprehensive validation study addresses one of the most significant questions in neurodegeneration: how a single genetic mutation in C9orf72 can manifest as distinct diseases (ALS, FTD, or combined phenotypes). The C9orf72 hexanucleotide repeat expansion represents the most common genetic cause of both familial ALS (~40%) and familial FTD (~25%), yet the mechanisms underlying phenotypic diversity remain largely unknown. This research gap represents a critical barrier to developing targeted therapeutics and understanding fundamental disease processes.

The study leverages patient-derived iPSCs and advanced molecular techniques to systematically dissect the cellular and molecular differences between disease presentations. By examining the full spectrum from RNA toxicity and dipeptide repeat protein accumulation to nucleocytoplasmic transport dysfunction and neuronal vulnerability patterns, this work will establish the mechanistic basis for phenotypic diversity. The findings will have immediate translational implications, potentially identifying biomarkers for disease prediction and stratification, while revealing novel therapeutic targets that could be applicable across the ALS-FTD spectrum. Understanding these mechanisms is essential for precision medicine approaches and could transform treatment strategies for thousands of patients worldwide.

This experiment directly tests predictions arising from the following hypotheses:

• Phase-Separated Organelle Targeting
• Cryptic Exon Silencing Restoration
• Cross-Seeding Prevention Strategy
• Glycine-Rich Domain Competitive Inhibition
• Low Complexity Domain Cross-Linking Inhibition

Experimental Protocol

Phase 1: Patient Cohort Assembly and Characterization (Months 1-3)

Recruit 150 participants: 50 C9orf72+ ALS patients, 50 C9orf72+ FTD patients, 25 C9orf72+ ALS/FTD patients, and 25 healthy controls with C9orf72 mutations but no symptoms. Perform comprehensive clinical phenotyping including ALSFRS-R, CDR-FTLD, and neuropsychological testing. Extract genomic DNA and perform Southern blot analysis to quantify hexanucleotide repeat length. Establish iPSC lines from all participants using episomal reprogramming.

Phase 2: Molecular Pathology Analysis (Months 4-8)

Generate motor neurons and cortical neurons from iPSCs using dual SMAD inhibition protocol. Perform RNA-seq on differentiated neurons at days 21, 35, and 50 to identify disease-specific transcriptional signatures. Quantify RNA foci formation using FISH with (GGGGCC)4 and (CCCCGG)4 probes. Measure dipeptide repeat protein (DPR) accumulation via immunofluorescence and Western blot for poly-GA, poly-GP, poly-GR, poly-PA, and poly-PR. Assess nuclear transport dysfunction using importin-β1 and Ran-GTP gradients.

Phase 3: Functional Characterization (Months 9-12)

Perform whole-cell patch-clamp electrophysiology to measure neuronal excitability, focusing on persistent sodium currents and action potential firing patterns. Conduct live-cell calcium imaging to assess synaptic function and calcium homeostasis. Use CRISPR-Cas9 to generate isogenic controls with corrected C9orf72 repeats. Perform proximity ligation assays to detect protein-protein interactions between DPRs and key cellular targets including nucleocytoplasmic transport machinery.

Phase 4: Mechanistic Validation (Months 13-15)

Transfect neurons with fluorescently-tagged constructs expressing different repeat lengths (2, 30, 100, 500 repeats) to establish dose-response relationships. Use antisense oligonucleotides targeting C9orf72 transcripts to validate therapeutic approaches. Perform proteomics analysis using TMT labeling and mass spectrometry to identify disease-specific protein networks. Validate key findings using CRISPR-edited mouse models with humanized C9orf72 loci.

Expected Outcomes

• 1. Identification of repeat length thresholds that differentiate ALS vs FTD presentation, with ALS patients showing >100 repeats and cortical neuron-specific vulnerability patterns
• 2. Discovery of disease-specific DPR accumulation patterns, with poly-GR/poly-PR showing >5-fold higher levels in ALS motor neurons vs FTD cortical neurons
• 3. Demonstration of differential nucleocytoplasmic transport defects, with ALS showing 40-60% reduction in nuclear import efficiency compared to 20-30% in FTD-only cases
• 4. Identification of 10-15 novel therapeutic targets through proteomics analysis, validated by >50% rescue of cellular phenotypes using targeted interventions
• 5. Establishment of biomarker signatures distinguishing disease subtypes with >85% accuracy using transcriptomic and proteomic profiles

Success Criteria

• • Statistical significance (p < 0.01) for all primary molecular readouts with effect sizes (Cohen's d) > 0.8 between disease groups
• • Successful completion of molecular analysis in >85% of recruited participants with high-quality iPSC-derived neurons
• • Reproducible phenotypes across ≥3 independent iPSC clones per participant, validated in mouse models
• • Identification of therapeutically targetable pathways with >50% rescue of key phenotypes in validation experiments
• • Development of predictive models for disease subtype with cross-validation accuracy >80%